Celltrion’s investigational COVID-19 antiviral antibody has shown a 100-fold reduction in viral load in a pre-clinical study.

The trial assessed the efficacy of two dosage amounts. Both dosage groups saw inflammation return to normal within six days and a shortened recovery time.

The company is now conducting additional efficacy and toxicity testing in pre-clinical trials and plans to begin human trials next month.